

Freedom of Information Request**Ref: UHB 17-767**

Date 22 December 2017

[REDACTED]

[REDACTED]

[REDACTED]

Thank you for your request for information under the Freedom of Information Act 2000. The Trusts response is as follows:

Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs for the conditions listed below:

- **Rheumatoid Arthritis**
- **Ankylosing Spondylitis**
- **Psoriatic Arthritis**
- **Psoriasis**
- **Hidradenitis Suppurativa**
- **Crohn's disease**
- **Ulcerative Colitis**

Please see table below. We are unable to provide a breakdown per condition as requested therefore the table below shows the total number of patients treated with the specified drugs.

Where the figures are fewer than 5, this has been denoted by **. Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. Therefore under Section 40(2) of the Freedom of Information Act 2000, we will not be disclosing this information at this time. Section 40 is the exemption for personal information

Number of patients treated	
TOTAL	1,960
Abatacept [Orencia]	48
Adalimumab [Biosimilar]	106
Adalimumab [Humira]	594
Apremilast [Otezla]	9
Baricitinib [Olumiant]	**
Brodalumab [Kyntheum]	0
Certolizumab [Cimzia]	15
Dimethyl fumarate [Skilarence]	8
Etanercept [Enbrel]	117
Etanercept Biosimilar [Benepali or Erelzi]	163
Golimumab [Simponi]	41
Guselkumab [Tremfya]	0
Infliximab [Remicade]	38
Infliximab Biosimilar [Inflectra, Remsima or Flixabi]	241
Ixekizumab [Taltz]	0
Rituximab [Mabthera]	262
Rituximab Biosimilar [Rixathon or Truxima]	44
Sarilumab [Kevzara]	0
Secukinumab [Cosentyx]	22
Tocilizumab [Ro Actemra]	48
Tofacitinib [Xeljanz]	0
Ustekinumab [Stelara]	118
Vedolizumab [Entyvio]	85

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Trust Secretary
 University Hospitals Bristol NHS Foundation Trust
 Trust Headquarters
 Marlborough Street
 Bristol
 BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

3

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely,

██████████
██████████